The prothrombin complex concentrates (PCC) are compounds derived from plasma that incorporates clotting factors dependent on vitamin K. They were developed in 1950 as a source of factor IX for the treatment of hemophilia B and currently their main indication is the reversal of the effects from oral anticoagulants vitamin K antagonists type in emergency situations. Other indications outlined for the use of PCC are the following: replacement therapy for factors II and X in some congenital and acquired defects, coagulopathy associated with severe liver disease, management of perioperative bleeding complications, massive trauma in anticoagulated patients and coagulopathies by sepsis.